PRR12

Across TCGA pan-cancer cohorts, PRR12 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PRR12 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PRR12 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRR12 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where PRR12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	IV	0.567	0.867	.023	9	view →
LUAD	OS	Quartile	All	0.927	1.000	.027	6	view →
CCRCC	DFS	Tertile	II,III,IV	0.768	0.429	.021	4	view →
GBM	DFS	Quartile	All	0.433	0.235	.005	4	view →
PDAC	OS	Median	All	0.472	0.610	.025	3	view →
LSCC	DFS	Tertile	II,III,IV	0.399	1.000	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PRR12–HNSC (DFS)

Open the HNSC breakdown →